Cata #: | Name of Product: | Price: |
HRP-3648 | Recombinant YFP-Human NCAM1 Protein | $250 |
Product Name: | Recombinant YFP-Human NCAM1 Protein |
Catalog #: | HRP-3648 |
Manufacture: | LD Biopharma, Inc. |
Intruduction: | Neural cell adhesion molecule 1 (NCAM1, also named CD56)gene encodesthis protein is a cell adhesion molecule which is involved in neuron-neuron adhesion, neurite fasciculation, outgrowth of neurites, etc. NCAM1 also acts as receptor for both rabies and Zika virus. Full-length extracellular domain of human NCAM1 cDNA (20-718aa, derived BC047244) was constructed with codon optimization gene synthesis and expressed with a human Alpha Fetal protein at N-terminal in E.coli as inclusion bodies. The final product was refolded using our unique “temperature shift inclusion body refolding” technology and chromatographically purified |
Gene Symbol: | NCAM1 ( CD56 ) |
Accession Number: | NP_000606 |
Species: | Human |
Package Size: | 50µg / Vial |
Composition: | 1.0 mg/ml, sterile-filtered, in 20 mM pH 8.0 Tris-HCl Buffer, with proprietary formulation of NaCl, KCl, EDTA, Sucrose, DTT and others. |
Storage: | In Liquid. Keep at -80°C for long term storage. Product is stable at 4 °C for at least two weeks. |
Key Reference: | ElMenshawy N, et al., Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple MyelomaPatients. Cancer Invest 39 (9), 777-782 (2021) Koumpis E, et al., CD56 expression in multiple myeloma: Correlation with poorprognostic markers but no effect on outcome. Pathol Res Pract 225, 153567 (2021) Zhao J. et al., Decreased Serum NCAM Levels Associated with Cognitive Impairment inVascular Dementia. Dis Markers 2021, 2792884 (2021) Lanier LL, et al.,Molecular and functional analysis of human natural killercell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol 146 (12), 4421-4426 (1991) |
Applications: |
|
Quality Control: | Purity: > 92 % by SDS-PAGE. |
Recombinant Protein Sequence: | MTLHRNEYGIASILDSYQCTAEISLADLATIFFAQFVQEATYKEVSKMVKDALTAIEKPTGDEQSSGCLENQLPAFLEELCHEKEILEKYGHSDCCSQSEEGRHNCFLAHKKPTPASIPLFQVPEPVTSCEAYEEDRETFMNKFIYEIARRHPFLYAPTILLWAARYDKIIPSCCKAENAVECFQTKAATVTKELRESSGGSHHHHHHGSLQVDIVPSQGEISVGESKFFLCQVAGDAKDKDISWFSPNGEKLTPNQQRISVVWNDDSSSTLTIYNANIDDAGIYKCVVTGEDGSESEATVNVKIFQKLMFKNAPTPQEFREGEDAVIVCDVVSSLPPTIIWKHKGRDVILKKDVRFIVLSNNYLQIRGIKKTDEGTYRCEGRILARGEINFKDIQVIVNVPPTIQARQNIVNATANLGQSVTLVCDAEGFPEPTMSWTKDGEQIEQEEDDEKYIFSDDSSQLTIKKVDKNDEAEYICIAENKAGEQDATIHLKVFAKPKITYVENQTAMELEEQVTLTCEASGDPIPSITWRTSTRNISSEEKASWTRPEKQETLDGHMVVRSHARVSSLTLKSIQYTDAGEYICTASNTIGQDSQSMYLEVQYAPKLQGPVAVYTWEGNQVNITCEVFAYPSATISWFRDGQLLPSSNYSNIKIYNTPSASYLEVTPDSENDFGNYNCTAVNRIGQESLEFILVQADTPSSPSIDQVEPYSSTAQVQFDEPEATGGVPILKYKAEWRAVGEEVWHSKWYDAKEASMEGIVTIVGLKPETTYAVRLAALNGKGLGEISAASEFKTQPVQGEPSAPKLEGQMGEDGNSIKVNLIKQDDGGSPIRHYLVRYRALSSEWKPEIRLPSGSDHVMLKSLDWNAEYEVYVVAENQQGKSKAAHFVFRTSAQPTAIPANGSPTSG |